Dyne Therapeutics stock gains, Sarepta falls after muscular dystrophy trial results
Dyne Therapeutics Inc. shares (DYN) jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental treatment DYNE-101 showed early dose-dependent results in patients with myotonic dystrophy type 1, Dyne said in a release. In patients with Duchenne muscular dystrophy, meanwhile, the experimental therapy Dyne-251 surpassed the level of production of the muscle protein dystrophin reported for the current standard of care for the condition, Dyne said. The company said it expects to report data for multiple, higher-dose cohorts from both trials in the second half of this year. Shares of Sarepta Therapeutics Inc. (SRPT), whose medication Exondys 51 or eteplirsen is designed to treat the same type of Duchenne muscular dystrophy as Dyne-251, fell more than 4% premarket on Wednesday. There have been no head-to-head trials comparing Dyne-251 to eteplirsen, Dyne said in its release. Dyne shares have gained 11.6% over the past 12 months, while Sarepta shares are down 22.9%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-03-24 0819ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?